Treatment with fibroblast growth factor 19 increases skeletal muscle fiber size, ameliorates metabolic perturbations and hepatic inflammation in 5/6 nephrectomized mice

[1]  F. Jaisser,et al.  Mineralocorticoid Receptor Antagonism Prevents the Synergistic Effect of Metabolic Challenge and Chronic Kidney Disease on Renal Fibrosis and Inflammation in Mice , 2022, Frontiers in Physiology.

[2]  D. Burrin,et al.  Fibroblast growth factor 15/19 expression, regulation, and function: An overview , 2022, Molecular and Cellular Endocrinology.

[3]  H. Vidal,et al.  Fibroblast growth factor 19 as a countermeasure to muscle and locomotion dysfunctions in experimental cerebral palsy , 2021, Journal of cachexia, sarcopenia and muscle.

[4]  R. Seeley,et al.  Intestinal-derived FGF15 protects against deleterious effects of vertical sleeve gastrectomy in mice , 2021, Nature Communications.

[5]  Q. Xiao,et al.  FGF19 protects skeletal muscle against obesity‐induced muscle atrophy, metabolic derangement and abnormal irisin levels via the AMPK/SIRT‐1/PGC‐α pathway , 2021, Journal of cellular and molecular medicine.

[6]  F. Gonzalez,et al.  The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer , 2021, Nature Reviews Gastroenterology & Hepatology.

[7]  Terence E. Ryan,et al.  Impaired muscle mitochondrial energetics is associated with uremic metabolite accumulation in chronic kidney disease. , 2020, JCI insight.

[8]  M. Mohammadi,et al.  Curtailing FGF19’s mitogenicity by suppressing its receptor dimerization ability , 2020, Proceedings of the National Academy of Sciences.

[9]  K. Uchiyama,et al.  Contribution of uremic dysbiosis to insulin resistance and sarcopenia. , 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  D. Fouque,et al.  A low aromatic amino-acid diet improves renal function and prevent kidney fibrosis in mice with chronic kidney disease , 2020, Scientific Reports.

[11]  D. Roussel,et al.  Accumulation of natriuretic peptides is associated with protein energy wasting and activation of browning in white adipose tissue in chronic kidney disease. , 2020, Kidney international.

[12]  H. Ellingsgaard,et al.  Muscle derived interleukin-6 increases exercise capacity by signaling in osteoblasts. , 2020, The Journal of clinical investigation.

[13]  D. Fan,et al.  Fibroblast Growth Factor 19–Mediated Up‐regulation of SYR‐Related High‐Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms‐Related Tyrosine Kinase 4 , 2020, Hepatology.

[14]  Shogo Yamamoto,et al.  Serum Endocrine Fibroblast Growth Factors as Potential Biomarkers for Chronic Kidney Disease and Various Metabolic Dysfunctions in Aged Patients , 2020, Internal medicine.

[15]  S. Berceli,et al.  Chronic kidney disease exacerbates ischemic limb myopathy in mice via altered mitochondrial energetics , 2019, Scientific Reports.

[16]  K. Safranow,et al.  Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21 , 2019, Kidney and Blood Pressure Research.

[17]  T. Bateman,et al.  Chronic kidney disease and aging differentially diminish bone material and microarchitecture in C57Bl/6 mice. , 2019, Bone.

[18]  G. Du,et al.  Effect of skeletal muscle phenotype and gender on fasting-induced myokine expression in mice. , 2019, Biochemical and biophysical research communications.

[19]  J. Renaud,et al.  Deletion of OPN in BSP knockout mice does not correct bone hypomineralization but results in high bone turnover. , 2019, Bone.

[20]  M. Kuro-o.  The Klotho proteins in health and disease , 2018, Nature Reviews Nephrology.

[21]  M. Yanishi,et al.  Related Factors of Osteosarcopenia in Kidney Transplant Recipients , 2018, Transplantation proceedings.

[22]  Hong Xian,et al.  Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. , 2017, Kidney international.

[23]  S. Kliewer,et al.  FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glycemia. , 2017, Cell metabolism.

[24]  D. Freyssenet,et al.  Fibroblast growth factor 19 regulates skeletal muscle mass and ameliorates muscle wasting in mice , 2017, Nature Medicine.

[25]  P. MacDonald,et al.  Urea impairs β cell glycolysis and insulin secretion in chronic kidney disease. , 2016, The Journal of clinical investigation.

[26]  J. Carrero,et al.  Muscle wasting in end-stage renal disease promulgates premature death: established, emerging and potential novel treatment strategies. , 2016, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[27]  R. M. Learned,et al.  Engineered fibroblast growth factor 19 reduces liver injury and resolves sclerosing cholangitis in Mdr2‐deficient mice , 2015, Hepatology.

[28]  A. Moschetta,et al.  Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23 , 2015, Nature Reviews Drug Discovery.

[29]  D. Fouque,et al.  Probiotics and chronic kidney disease. , 2015, Kidney international.

[30]  W. Mitch,et al.  Mechanisms of muscle wasting in chronic kidney disease , 2014, Nature Reviews Nephrology.

[31]  Masanori Tamaki,et al.  Chronic kidney disease reduces muscle mitochondria and exercise endurance and its exacerbation by dietary protein through inactivation of pyruvate dehydrogenase. , 2014, Kidney international.

[32]  J. Kieswich,et al.  Elevated hepatic 11β-hydroxysteroid dehydrogenase type 1 induces insulin resistance in uremia , 2014, Proceedings of the National Academy of Sciences.

[33]  J. Axelsson,et al.  Impaired postprandial fibroblast growth factor (FGF)-19 response in patients with stage 5 chronic kidney diseases is ameliorated following antioxidative therapy. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[34]  W. Mitch,et al.  Stat3 activation links a C/EBPδ to myostatin pathway to stimulate loss of muscle mass. , 2013, Cell metabolism.

[35]  M. Febbraio,et al.  Muscles, exercise and obesity: skeletal muscle as a secretory organ , 2012, Nature Reviews Endocrinology.

[36]  Y. Nabeshima,et al.  Decreased renal α-Klotho expression in early diabetic nephropathy in humans and mice and its possible role in urinary calcium excretion. , 2012, Kidney international.

[37]  A. Cheung,et al.  OPPORTUNITY™: a large-scale randomized clinical trial of growth hormone in hemodialysis patients. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  S. Kliewer,et al.  FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis , 2011, Science.

[39]  W. Mitch,et al.  Pharmacological inhibition of myostatin suppresses systemic inflammation and muscle atrophy in mice with chronic kidney disease , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[40]  M. Fasshauer,et al.  Fibroblast Growth Factor 19 Serum Levels: Relation to Renal Function and Metabolic Parameters , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[41]  N. Binkley,et al.  Beyond FRAX: it's time to consider "sarco-osteopenia". , 2009, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[42]  G. Chertow,et al.  Frailty and chronic kidney disease: the Third National Health and Nutrition Evaluation Survey. , 2009, The American journal of medicine.

[43]  W. Mitch,et al.  Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. , 2006, Journal of the American Society of Nephrology : JASN.

[44]  S. Kliewer,et al.  Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. , 2005, Cell metabolism.

[45]  R. Soriano,et al.  Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. , 2004, Endocrinology.

[46]  M. Samore,et al.  Effects of body size and body composition on survival in hemodialysis patients. , 2003, Journal of the American Society of Nephrology : JASN.

[47]  F. Schaefer,et al.  Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia. , 2001, The Journal of clinical investigation.

[48]  W. Mitch,et al.  The acidosis of chronic renal failure activates muscle proteolysis in rats by augmenting transcription of genes encoding proteins of the ATP-dependent ubiquitin-proteasome pathway. , 1996, The Journal of clinical investigation.

[49]  A. Garber,et al.  Abnormal carbohydrate metabolism in chronic renal failure. The potential role of accelerated glucose production, increased gluconeogenesis, and impaired glucose disposal. , 1978, The Journal of clinical investigation.

[50]  J. Trotter,et al.  NGM 282 for treatment of non-alcoholic steatohepatitis : a multicentre , randomised , double-blind , placebo-controlled , phase 2 trial , 2018 .

[51]  W. Aoi.  Characteristics of Skeletal Muscle as a Secretory Organ , 2017 .

[52]  W. Cheung,et al.  A pegylated leptin antagonist ameliorates CKD-associated cachexia in mice. , 2014, Journal of the American Society of Nephrology : JASN.

[53]  J. Montani,et al.  Effect of chronic renal failure on the hepatic, intestinal, and renal expression of bile acid transporters. , 2014, American journal of physiology. Renal physiology.

[54]  H. Soula,et al.  p-Cresyl sulfate promotes insulin resistance associated with CKD. , 2013, Journal of the American Society of Nephrology : JASN.

[55]  R. Casaburi,et al.  Metabolic and morphometric profile of muscle fibers in chronic hemodialysis patients. , 2012, Journal of applied physiology.